Drug discovery

#AI #Artificial intelligence (AI) #Drug discovery #R&D

Industry partnership to boost AI in drug discovery

A new partnership will bring together Microsoft’s computational services, cloud and artificial intelligence (AI) and Novo Nordisk’s drug discovery, development and data science capabilities. Through the agreement, Microsoft will provide AI technology, foundational science models and expertise and work alongside Novo Nordisk’s data scientists and domain experts to accelerate the… Read More

#Business & Investment #News

Molecules
#Drug discovery #Fragment-based drug discovery #Hit identification #Webinar

An introduction into fragment-based drug discovery: webinar

Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process.   Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec, is now available to watch online. … Read More

Webinar date:
Brought to you by WuXi AppTec
#Webinars

CT scans of the brain
#Alzheimer's #Cognitive impairment #Drug discovery #US patent

Potential Alzheimer’s drug receives US patent

The United States Patent Office (USPTO) has issued a patent covering drug candidate ACD856, which is currently being developed to treat Alzheimer’s disease and other disorders with cognitive impairment. ACD856 is part of AlzeCure Pharma’s NeuroRestore platform, which it is hoped could provide treatments for Alzheimer’s, Parkinson’s disease and depression. Read More

#News

Molecules
#Drug discovery #Fragment-based drug discovery #Hit identification

An introduction into fragment-based drug discovery: webinar

Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process.   Watch this free event, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec.  Fragments are… Read More

#News

#Cancer research #Drug discovery #European Society for Medical Oncology #Oncology

This week in drug discovery (5-9 September)

News round-up for 5-9 September by DDW Digital Content Editor Diana Spencer Cancer research has been making headlines over the last seven days in the build-up to the European Society for Medical Oncology (ESMO) Congress 2022. Notably, it was a mixed week for PARP inhibitor olaparib, which was approved by regulator… Read More

#News

#Drug discovery #Pharmaceutical industry #Phenotyping #PhoreMost #Roche

PhoreMost and Roche enter drug discovery partnership

Roche and UK-based biopharmaceutical company PhoreMost have agreed to a multi-project target discovery collaboration. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for preclinical success-based milestones. PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward disease-relevant pathways nominated by Roche. Novel targets identified… Read More

#Business & Investment #News

#Assays #Drug discovery #Lab analytics

Make the switch to label-free interaction analysis

Conventional bioassays rely on enzyme or fluorescent labels to detect biomolecular interactions. These come with challenges that lead to skewed and inaccurate results. In this eBook, learn how label-free interaction techniques drive: Faster analysis – fewer sample preparation steps More sensitive analysis – enabling close observation of small and fragment molecules… Read More

#Intelligence #Resources

Medical researchers
#Biopharmaceuticals #Drug discovery #Start-ups #Venture Lab

More start-ups join Venture Lab programme

The latest cohort of companies have joined the Venture Lab acceleration programme for early-stage companies, created by non-profit foundation the BioInnovation Institute (BII). Designed to help build research-based ideas with high-growth commercial potential into viable start-ups, BII’s 12-month Venture Lab programme supports business acceleration, scientific and team development. It provides… Read More

#News #Start-up Zone

#Cell and gene therapy #Covid-19 #Drug discovery #Manufacturing

The challenges and trends of cell & gene therapies 

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year.   There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. This area of medicine,… Read More

#Exclusive Content #Opinion #Trends & Analysis

#AI #Drug discovery #Machine learning #Oncology

The role of machine learning in cancer drug development

Throughout the continuum of drug development, from target discovery to patient selection, machine learning approaches are being adopted to reliably mine vast amounts of data and make predictions with higher accuracy Anita Ramanathan discusses how machine learning is currently used across different stages of cancer research.  Applying… Read More

#Cancer Research #Exclusive Content

San Diego skyline
#BioLabs #Charles River #Drug development #Drug discovery

Charles River expands contract vivarium space on West Coast

Charles River Laboratories has added five new Charles River Accelerator and Development Lab (CRADL) locations in California and Washington.  CRADL provides flexible, turnkey vivarium rental space supported by Charles River’s technical and veterinary support expertise in key biohubs. This allows clients to start new projects, accelerating the early stage… Read More

#Business & Investment #News

Vials for medical research
#Antibodies #Biomedical research #Drug development #Drug discovery #In vitro

New anti-evolocumab antibodies could aid drug development

Bio-Rad Laboratories has introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels.  These sequence-defined, recombinant antibodies are… Read More

#News

#Breast cancer #Drug discovery #Oncology

Nitric oxide could form treatment approach for breast cancer

A new therapeutic approach for triple negative breast cancer using nitric oxide is being explored by researchers at the medical research centre CÚRAM. Amir Abdo Alsharabasy, a CÚRAM doctoral candidate working in the laboratory of Professor Abhay Pandit, is working on the design of nitric oxide scavengers to form a… Read More

#News

#Drug discovery #Spinal cord injury #Stem cells

Latent stem cells could repair spinal cord damage

A group of latent stem cells could be the key to developing new therapeutic approaches to treat brain and spinal cord injuries, research shows. Scientists at the Francis Crick Institute identified a group of latent stem cells in mice which respond to injury in the central nervous system. If the… Read More

#News

#Antibody #Drug discovery #Monoclonal antibodies #Webinar

Webinar – applications in early monoclonal antibody discovery

In this webinar, Christina Pettus, Senior Scientist, Charles River Laboratories, provides insights into how the company incorporates Octet Bio-Layer Interferometry (BLI) into its monoclonal antibody discovery workflow for discovery campaigns, antibody optimisation, and IgG characterisation. The webinar elaborates on the use of the Octet BLI for quality control of proteins,… Read More

#News

#Drug discovery #Organoids

Latest guide: A life scientist’s how-to guide for organoids

Learn best practices to consider for organoid work, as well as how to use Corning Matrigel matrix and other products to support research. Organoids have gained popularity over the years due to their ability to self-organise into “mini-organs” capable of recapitulating their respective organ-specific functions. Read More

#News